In contrast, bortezomib efficiently blocked the constitutive and b1 and b5 immunosubunits with- out inhibiting the b2 or b2i subunits.
The observed difference in competition efficiency of Ada-Ahx3-L3-VS and bor- tezomib is in agreement with their known different inhibitory potency.